AU2013334943A1 - Combination - Google Patents

Combination Download PDF

Info

Publication number
AU2013334943A1
AU2013334943A1 AU2013334943A AU2013334943A AU2013334943A1 AU 2013334943 A1 AU2013334943 A1 AU 2013334943A1 AU 2013334943 A AU2013334943 A AU 2013334943A AU 2013334943 A AU2013334943 A AU 2013334943A AU 2013334943 A1 AU2013334943 A1 AU 2013334943A1
Authority
AU
Australia
Prior art keywords
methyl
chloro
amino
ethyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013334943A
Other languages
English (en)
Inventor
Tona M. Gilmer
Rakesh Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013334943A1 publication Critical patent/AU2013334943A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: GLAXOSMITHKLINE LLC
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
AU2013334943A 2012-10-22 2013-10-21 Combination Abandoned AU2013334943A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716780P 2012-10-22 2012-10-22
US61/716,780 2012-10-22
PCT/US2013/065827 WO2014066202A1 (en) 2012-10-22 2013-10-21 Combination

Publications (1)

Publication Number Publication Date
AU2013334943A1 true AU2013334943A1 (en) 2015-05-14

Family

ID=50545138

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013334943A Abandoned AU2013334943A1 (en) 2012-10-22 2013-10-21 Combination

Country Status (12)

Country Link
US (1) US20150272952A1 (enExample)
EP (1) EP2908815A4 (enExample)
JP (1) JP2015534986A (enExample)
KR (1) KR20150074097A (enExample)
CN (1) CN104902899A (enExample)
AU (1) AU2013334943A1 (enExample)
BR (1) BR112015008924A2 (enExample)
CA (1) CA2889051A1 (enExample)
IN (1) IN2015DN03909A (enExample)
MX (1) MX2015005113A (enExample)
RU (1) RU2015119245A (enExample)
WO (1) WO2014066202A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US8835450B2 (en) * 2009-10-08 2014-09-16 Glaxosmithkline Llc Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy

Also Published As

Publication number Publication date
RU2015119245A (ru) 2016-12-10
EP2908815A4 (en) 2016-06-22
US20150272952A1 (en) 2015-10-01
JP2015534986A (ja) 2015-12-07
CN104902899A (zh) 2015-09-09
MX2015005113A (es) 2015-10-29
EP2908815A1 (en) 2015-08-26
WO2014066202A1 (en) 2014-05-01
KR20150074097A (ko) 2015-07-01
BR112015008924A2 (pt) 2017-07-04
IN2015DN03909A (enExample) 2015-10-02
CA2889051A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
AU2012205601A1 (en) Combination
US20160213672A1 (en) Combination
AU2010303363B2 (en) Combination
CN102770026B (zh) 组合
WO2011146712A1 (en) Combination
EP2485594B1 (en) Combination
US20130137701A1 (en) Combination
US20150272952A1 (en) Combination
US20150094283A1 (en) Combination
US20150272950A1 (en) Combination

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVARTIS AG

Free format text: FORMER APPLICANT(S): GLAXOSMITHKLINE LLC

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted